A multivalent inactivated Escherichia coli vaccine for forest musk deer by using serotypes O4,O26,and O139 with Al（OH）3 adjuvant was prepared.The vaccine did not cause any adverse reactions in forest musk deer.The i...A multivalent inactivated Escherichia coli vaccine for forest musk deer by using serotypes O4,O26,and O139 with Al（OH）3 adjuvant was prepared.The vaccine did not cause any adverse reactions in forest musk deer.The immunogenic effects of the vaccine were experimentally investigated in pregnant and young forest musk deer.The serum antibody titers of pregnant and young forest musk deer were determined by performing the micro-agglutination test.The serum antibody titers of pregnant forest musk deer were more stable from 35th to 68th d after the third vaccination,and the serum antibody titers of four pregnant forest musk deer were maintained 25,25,25,and 24 on 68th d after the third vaccination.Young forest musk deer showed serum antibody titers which were obtained due to nursing.Young forest musk deer were administered the first intramuscular vaccine injection at an age of approximately 60 days due to a fall in maternal antibody titers.The serum antibody titers of young forest musk deer were higher after the third vaccination and maintained at approximately the same level until they were 137 days old.The maternal antibodies and the antibodies produced by young forest musk deer could be helpful for protecting the young musk deer from the infections of pathogenic Escherichia coli strains（serotypes O4,O26,and O139）for 137 days after birth（during the nursing period and the period when the forest musk deer were susceptible to diseases）.展开更多
The study and entire laboratory works were conducted from December 2014 to April 2015 in National Veterinary Institute, Bishoftu, Ethiopia. Formaldehyde inactivated Montanide ISA70 based Mycoplasma gallisepticum (MG) ...The study and entire laboratory works were conducted from December 2014 to April 2015 in National Veterinary Institute, Bishoftu, Ethiopia. Formaldehyde inactivated Montanide ISA70 based Mycoplasma gallisepticum (MG) trial vaccine strain was confirmed the identity with known primer using PCR from locally isolates of National Veterinary Institute of Ethiopia. This study was aimed to develop formaldehyde inactivated Montanide ISA70 based MG vaccine in Ethiopia. It can help to device strategies in controlling the disease mainly through developing more effective vaccine which will replace the currently being imported vaccines by some farms. After culturing procedure, oil based inactivated MG trial vaccine was produced in suitable clean and secure accommodation. In this study, among different isolates, local isolate of Samuel farm in NVI was prepared and evaluated in chickens. The amount of immune antigen per 0.5 ml of the dose was 107 Colony forming units (CFU) of the bacteria. The trail vaccine was prepared and evaluated at the age of 16 weeks of chickens;the chickens were randomly divided into three groups (A, B and C), each having twenty birds (10 male and 10 female). Each of group B was vaccinated group of imported-live vaccine with 30 μl intraocularly for comparing with inactivated trial vaccine, each bird of group C was inoculated with 0.5 ml indigenous or trial vaccine subcutaneously at mid neck region and group A was used as a control then challenge tests were performed. After challenge test, among non-vaccinated chickens (control or group A) 2 chickens were died (10%), thicken and cloudy appearance of the air sac showed 18 (90%), 2 chickens were not showed thickened and cloudy air sack (10%). Although among vaccinated group (inactivated vaccine or group C), all chickens did not show clinical signs or post mortem changes (100%). From attenuated imported live vaccine (group B), no clinical signs or post mortem changes were observed (100%). It was concluded that oil based MG vaccine induces protective level of anti MG antibodies in chickens.展开更多
基金Supported by Youth Foundation of Education Department in Sichuan Province(07ZB060)Scientific and Technological Supporting Project in Science and Technology Bureau of Sichuan Province(2009SZ0228)~~
文摘A multivalent inactivated Escherichia coli vaccine for forest musk deer by using serotypes O4,O26,and O139 with Al（OH）3 adjuvant was prepared.The vaccine did not cause any adverse reactions in forest musk deer.The immunogenic effects of the vaccine were experimentally investigated in pregnant and young forest musk deer.The serum antibody titers of pregnant and young forest musk deer were determined by performing the micro-agglutination test.The serum antibody titers of pregnant forest musk deer were more stable from 35th to 68th d after the third vaccination,and the serum antibody titers of four pregnant forest musk deer were maintained 25,25,25,and 24 on 68th d after the third vaccination.Young forest musk deer showed serum antibody titers which were obtained due to nursing.Young forest musk deer were administered the first intramuscular vaccine injection at an age of approximately 60 days due to a fall in maternal antibody titers.The serum antibody titers of young forest musk deer were higher after the third vaccination and maintained at approximately the same level until they were 137 days old.The maternal antibodies and the antibodies produced by young forest musk deer could be helpful for protecting the young musk deer from the infections of pathogenic Escherichia coli strains（serotypes O4,O26,and O139）for 137 days after birth（during the nursing period and the period when the forest musk deer were susceptible to diseases）.
文摘The study and entire laboratory works were conducted from December 2014 to April 2015 in National Veterinary Institute, Bishoftu, Ethiopia. Formaldehyde inactivated Montanide ISA70 based Mycoplasma gallisepticum (MG) trial vaccine strain was confirmed the identity with known primer using PCR from locally isolates of National Veterinary Institute of Ethiopia. This study was aimed to develop formaldehyde inactivated Montanide ISA70 based MG vaccine in Ethiopia. It can help to device strategies in controlling the disease mainly through developing more effective vaccine which will replace the currently being imported vaccines by some farms. After culturing procedure, oil based inactivated MG trial vaccine was produced in suitable clean and secure accommodation. In this study, among different isolates, local isolate of Samuel farm in NVI was prepared and evaluated in chickens. The amount of immune antigen per 0.5 ml of the dose was 107 Colony forming units (CFU) of the bacteria. The trail vaccine was prepared and evaluated at the age of 16 weeks of chickens;the chickens were randomly divided into three groups (A, B and C), each having twenty birds (10 male and 10 female). Each of group B was vaccinated group of imported-live vaccine with 30 μl intraocularly for comparing with inactivated trial vaccine, each bird of group C was inoculated with 0.5 ml indigenous or trial vaccine subcutaneously at mid neck region and group A was used as a control then challenge tests were performed. After challenge test, among non-vaccinated chickens (control or group A) 2 chickens were died (10%), thicken and cloudy appearance of the air sac showed 18 (90%), 2 chickens were not showed thickened and cloudy air sack (10%). Although among vaccinated group (inactivated vaccine or group C), all chickens did not show clinical signs or post mortem changes (100%). From attenuated imported live vaccine (group B), no clinical signs or post mortem changes were observed (100%). It was concluded that oil based MG vaccine induces protective level of anti MG antibodies in chickens.
